CRIS Current Research Information System

BRANDI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.466
AS - Asia 11.450
EU - Europa 9.597
AF - Africa 810
SA - Sud America 731
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 11
AN - Antartide 1
Totale 37.080
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.336
SG - Singapore 3.794
CN - Cina 3.163
GB - Regno Unito 2.244
VN - Vietnam 2.227
IT - Italia 1.469
DE - Germania 1.254
SE - Svezia 1.226
HK - Hong Kong 860
IN - India 647
RU - Federazione Russa 610
IE - Irlanda 555
BR - Brasile 523
CH - Svizzera 458
FR - Francia 379
UA - Ucraina 326
NL - Olanda 282
KR - Corea 247
FI - Finlandia 206
ZA - Sudafrica 203
CI - Costa d'Avorio 189
TG - Togo 179
EE - Estonia 160
SC - Seychelles 136
JP - Giappone 124
JO - Giordania 98
ID - Indonesia 95
AR - Argentina 89
BG - Bulgaria 89
AT - Austria 85
CA - Canada 85
NG - Nigeria 64
BE - Belgio 55
PL - Polonia 39
MX - Messico 37
GR - Grecia 34
EC - Ecuador 31
CL - Cile 30
TR - Turchia 25
PY - Paraguay 23
IR - Iran 22
HR - Croazia 21
IQ - Iraq 21
ES - Italia 20
BD - Bangladesh 19
RO - Romania 19
LT - Lituania 17
CO - Colombia 16
UZ - Uzbekistan 13
MY - Malesia 12
AE - Emirati Arabi Uniti 11
AU - Australia 10
LB - Libano 10
PT - Portogallo 10
PE - Perù 9
PK - Pakistan 9
TN - Tunisia 9
CZ - Repubblica Ceca 8
PH - Filippine 8
PS - Palestinian Territory 8
SA - Arabia Saudita 8
KZ - Kazakistan 7
VE - Venezuela 7
A2 - ???statistics.table.value.countryCode.A2??? 6
DK - Danimarca 6
EG - Egitto 6
HU - Ungheria 5
MA - Marocco 5
TW - Taiwan 5
KE - Kenya 4
AZ - Azerbaigian 3
DZ - Algeria 3
IL - Israele 3
NZ - Nuova Zelanda 3
SI - Slovenia 3
SK - Slovacchia (Repubblica Slovacca) 3
UY - Uruguay 3
XK - ???statistics.table.value.countryCode.XK??? 3
BB - Barbados 2
BY - Bielorussia 2
DM - Dominica 2
EU - Europa 2
GH - Ghana 2
LK - Sri Lanka 2
LV - Lettonia 2
MD - Moldavia 2
RS - Serbia 2
SN - Senegal 2
TH - Thailandia 2
UG - Uganda 2
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
CD - Congo 1
CG - Congo 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
GI - Gibilterra 1
Totale 37.065
Salva come PNG Salva come JPEG
Città #
Singapore 2.484
Southend 1.998
Ashburn 1.422
Chandler 1.329
Fairfield 1.286
Hong Kong 852
Dong Ket 832
Santa Clara 687
Dallas 662
Princeton 634
Wilmington 600
Houston 598
Hefei 587
Woodbridge 578
Seattle 536
Dublin 505
Beijing 499
Bern 438
Cambridge 424
Boardman 384
Ann Arbor 369
Bologna 345
Ho Chi Minh City 339
Hanoi 257
Seoul 234
Los Angeles 223
Nanjing 209
New York 203
Westminster 202
Jacksonville 190
Abidjan 189
Lomé 179
Padova 171
Helsinki 152
Berlin 149
Jinan 123
Redondo Beach 122
San Diego 119
Tokyo 119
Menlo Park 112
Buffalo 110
Milan 106
Medford 99
Amman 97
Saint Petersburg 96
Shenyang 90
Redmond 88
Sofia 85
Hebei 77
Frankfurt am Main 75
Changsha 72
Turin 70
Florence 65
Jakarta 65
Rome 64
São Paulo 63
Nanchang 62
Guangzhou 58
Shanghai 58
Chicago 57
Mülheim 57
Bengaluru 55
Brussels 53
Munich 51
Jiaxing 48
London 46
Nuremberg 46
Vienna 46
Abeokuta 45
Tianjin 43
Des Moines 41
Zhengzhou 41
Toronto 39
Yubileyny 39
Haiphong 37
Redwood City 37
Hangzhou 36
Dearborn 35
Olalla 34
Lappeenranta 33
Norwalk 32
Pune 32
Kuban 31
Bremen 30
Brooklyn 30
Bühl 29
Phoenix 29
Fremont 27
Taizhou 27
Da Nang 26
Falkenstein 26
San Francisco 26
Mahé 25
Montreal 25
Council Bluffs 24
Haikou 24
Kunming 24
Paris 24
Tongling 24
Warsaw 24
Totale 24.299
Salva come PNG Salva come JPEG
Nome #
Asbestos: a hidden player behind the cholangiocarcinoma increase? Findings from a case–control analysis 373
Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms 365
Adjuvant treatment in biliary tract cancer 317
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 272
SUSTAINED COMPLETE RESPONSE OF ADVANCED HEPATOCELLULAR CARCINOMA WITH METRONOMIC CAPECITABINE: A REPORT OF THREE CASES 265
An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone 260
Circadian variations of rectal cell proliferation in patients affected by advanced colorectal cancer. 238
A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. 236
Adjuvant chemotherapy for resected colorectal cancer metastases: literature revision and meta-analysis 231
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases. 227
An atlas for clinical target volume definition, including elective nodal irradiation in definitive radiotherapy of biliary cancer 221
Brain Metastases from Biliary Tract Cancer: A Monocentric Retrospective Analysis of 450 Patients 217
Antiprotease strategy in combination with gemcitabine as a putative novel therapeutic approach for pancreatic cancer treatment 216
Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations 215
Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study. 210
Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib. 209
Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study 208
Antitumoral Efficacy of Two Turmeric Extracts According to Different Extraction Methods in Hepatocellular Carcinoma Cell Lines 204
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments 202
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 198
Clinical Target Volume in Biliary Carcinoma: A Systematic Review of Pathological Studies. 194
Chemotherapy followed by chemoradiotherapy in locally advanced pancreatic cancer:A literature review and report of two cases 193
Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study 192
Second surgery or chemotherapy for relapse after radical resection of colorectal cancer metastases. 192
Changes in the surgical approach to hilar cholangiocarcinoma during an 18-year period in a Western single center 192
219 MiR-21 expression correlates with prognosis in extrahepatic radically resected cholangiocarcinomas treated with gemcitabine-based adjuvant chemotherapy 189
Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention 189
Genome-wide analysis identifies MEN1 and MAX mutations and a neuroendocrine-like molecular heterogeneity in Quadruple WT GIST 187
HIV enteropathy: undescribed ultrastructural changes of duodenal mucosa and their regression after triple antiviral therapy. A case report 186
Can the tyrosine kinase inhibitors trigger metabolic encephalopathy in cirrhotic patients? 184
Cell proliferation and ultrastructural changes of the duodenal mucosa of patients affected by familial adenomatous polyposis. 184
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept 184
Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST) 182
Complete remission of primary colon cancer in a metastatic patient treated with CPT-11 plus capecitabine. 182
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 182
Molecular imaging and targeted therapies in oncology: new concepts in treatment response assessment. a collection of cases. 181
Surveillance for Hepatocellular Carcinoma Also Improves Survival of Incidentally Detected Intrahepatic Cholangiocarcinoma Arisen in Liver Cirrhosis 181
Combined low densities of FoxP3+ and CD3+ tumor-infiltrating lymphocytes identify stage II colorectal cancer at high risk of progression 180
Risk of duodenal adenomas in familial adenomatous polyposis to progress toward advanced neoplastic disease 179
Venous thromboembolism and port-related thrombosis in metastatic colorectal cancer patients: a monocenter experience. 179
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 179
Asbestos: a putative risk factor for intrahepatic cholangiocarcinoma 176
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report 176
Second-line treatment in advanced biliary tract cancer: Today and tomorrow 176
The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma 175
Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene. 174
Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST) 173
ACTIVATED NF-KB IN COLORECTAL CANCER: PREDICTIVE OR PROGNOSTIC FACTOR? 171
In Reply 171
Bone metastases in biliary cancers: A multicenter retrospective survey 171
An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor 171
INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS 171
Heterotopic segmental liver transplantation on splenic vessels after splenectomy with delayed native hepatectomy after graft regeneration: A new technique to enhance liver transplantation 170
Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis 169
Treatment of colorectal cancer liver metastases 168
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies 165
Evolving knowledge in surgical oncology of pancreatic cancer: from theory to clinical practice-a fifteen-year journey at a tertiary referral centre 165
null 164
Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice 162
Cholangiocarcinoma: From risk to prevention? 159
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. 159
Dyskerin expression in human fetal, adult and neoplastic intrahepatic bile ducts: Correlations with cholangiocarcinoma aggressiveness 158
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 157
Interactions between commensal bacteria and gut sensorimotor function in health and disease. 156
Molecular imaging suggests efficacy of bevacizumab beyond the second line in advanced colorectal cancer patients. 156
Postsorafenib systemic treatments for hepatocellular carcinoma: Questions and opportunities after the regorafenib trial 154
Breast carcinoma presenting as linitis plastica 153
The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation 153
Searching for novel multimodal treatments in oligometastatic pancreatic cancer 152
A multicenter survey on second-line chemotherapy for advanced biliary tract cancer 151
Effectiveness and cost-effectiveness of peri-operative versus post-operative chemotherapy for resectable colorectal liver metastases. 151
Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements 151
Urease-Positive Bacteria Other than Helicobacter pylori in Human Gastric Juice and Mucosa 150
Intrahepatic cholangiocarcinoma: primary liver resection and aggressive multimodal treatment of recurrence significantly prolong survival. 150
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies 150
BIFIDOBACTERIACEAE IN THE ACHLORIDRIC STOMACH 149
Occupational exposure to asbestos and risk of cholangiocarcinoma: a population-based case-control study in four Nordic countries 149
Efficacy of weekly docetaxel in locally advanced cardiac angiosarcoma 148
Capecitabine(CAP) based regimens vs infusional 5FU/AF in metastatic colorectal cancer cost/effectivness: the differences across the atlantic ocean 148
Second-line chemotherapy in patients with biliary tract cancer. 148
Long-term survival of two patients with recurrent pancreatic acinar cell carcinoma treated with radiofrequency ablation: A case report. 148
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience 147
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: An analysis of the phase 3 REACH study 145
Metronomic capecitabine in advanced hepatocellular carcinoma patients:a phase II study. 144
Chemotherapy in Patients with Advanced Cholangiocarcinoma 142
null 142
High prevalence of asbestos exposure in bile duct cancer patients 140
Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer 139
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. 139
Intestinal microflora and digestive toxicity of irinotecan in mice. 139
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma 138
Diagnosis and treatment of cholangiocarcinoma in Italy: A Delphi consensus statement 138
Impact of adjuvant chemotherapy on time to relapse in cholangiocarcinoma. 138
EXPOSURE TO ASBESTOS: A PUTATIVE UNKNOWN RISK FACTOR FOR INTRAHEPATIC CHOLANGIOCARCINOMA 138
KRAS and BRAF mutational status as selective criteria for targeted therapy in cholangiocarcinoma. 137
Plasma membrane localization of human equilibrative nucleoside transporter 1 (hENT-1) to predict better outcome of adjuvant gemcitabine in cholangiocarcinoma (CC) patients. 137
Genomic And Genetic Characterization of Cholangiocarcinoma Identifies Therapeutics Targets for Tyrosine Kinase Inhibitors 136
Bifidobacteriaceae usually colonize human hypochloridric stomach 136
Estimation of the Survival Benefit Obtainable From Screening for the Early Detection of Pancreatic Cancer 136
Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms. A review of the literature and a long-standing experience of a referral center 136
Totale 17.840
Salva come PNG Salva come JPEG
Categoria #
all - tutte 116.837
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 116.837
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.434 0 0 0 0 0 189 91 160 356 141 157 1.340
2021/20225.060 418 190 243 327 379 227 167 286 483 313 1.168 859
2022/20236.072 659 808 312 673 401 445 192 349 979 214 423 617
2023/20241.591 194 268 113 136 113 331 73 83 51 103 58 68
2024/20256.410 253 1.041 643 502 1.034 304 444 173 104 424 280 1.208
2025/20268.510 1.542 1.476 1.892 1.169 1.655 776 0 0 0 0 0 0
Totale 38.015